TRANSBIOLOGICS

Cultures of microorganisms other than for medical and veterinary use, namely, genetically modified microorganisms that express interfering molecules that inhibit the expression of target genes; Cultures of microorganisms other than for medical or veterinary use, namely, genetically modified microorganisms for use in therapeutic treatment of pathogens in plants, namely, microorganisms that express RNA-based therapeutic agents that inhibit the expression of target pathogen genes; Cultures of microorganisms other than for medical or veterinary use, namely, probiotic compositions for use in therapeutic treatment of pathogens in plants, namely, genetically engineered bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Probiotic compositions use as ingredients for food and beverages, namely, genetically engineered probiotic bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Probiotic compositions for use as ingredients for food and beverages, namely, genetically modified probiotic bacteria configured to produce bioavailable nutritional compounds; Cultures of microorganisms for medical or agricultural use, namely, genetically modified endophytic bacteria for use in therapeutic treatment of pathogens in plants

Cultures of microorganisms for medical and veterinary use, namely, genetically modified microorganisms that express interfering molecules that inhibit the expression of target genes; Biological preparations for the treatment of infectious diseases in animals, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target animal pathogen genes; Biological preparations for the treatment of infectious diseases in plants, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target plant pathogen genes; Biological preparations for the treatment of viral infections in plants, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target viral pathogen genes; Biological preparations for the treatment of bacterial infections in animals, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target bacterial pathogen genes; Biological preparations for the treatment of fungal diseases, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target fungal pathogen genes; Cultures of microorganisms for medical or veterinary use, namely, genetically modified microorganisms for use in therapeutic treatment of pathogens in animals, namely, microorganisms that express RNA-based therapeutic agents that inhibit the expression of target pathogen genes; Probiotic preparations for medical or veterinary use, namely, probiotic compositions for use in therapeutic treatment of pathogens in animals, namely, genetically engineered bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Cultures of microorganisms for medical or veterinary use, namely, genetically modified enteric bacteria for use in therapeutic treatment of pathogens in animals; Medical, biological and pharmaceutical preparations for the prevention and treatment of infectious diseases in plants and animals; biological RNA-based therapeutic agents for the prevention and treatment of infectious diseases in plants and animals; Cultures of microorganisms for medical or veterinary use, namely, biological RNA-based therapeutic agents that inhibit the expression of target genes in plant pests and herbivores